i4i Connect is aimed at small to medium-sized enterprises (SMEs) in need of a funding boost to reach the next stage in the development pathway.
Offering between £50,000-£150,000 over a 6-12 month period, its primary aim is to help SMEs get to a point where they can apply for further funding, in particular for a full i4i Product Development Award (PDA), or to support projects at any stage of the translational research and development pathway to further de-risk them for follow on investment.
This will enable accelerated development of promising medical technologies, in line with recommendations from the Government’s Accelerated Access Review.
- Lead applicants must be from an SME
- Lead applicants must be based in England
- Projects must be £50,000-150,000 in value
- Projects must be 6-12 months in duration
- Upon acceptance of i4i Connect funding, applicants agree to be bound by the terms of the NIHR standard research contract and are expected to sign the contract within four weeks of the award notice or the award may be withdrawn
For i4 Connect, NIHR will fund:
- Research and development of medical devices, active implantable devices and in vitro diagnostic devices as defined by the relevant EU directives, across all areas of existing or emerging healthcare needs
- Product or technology development required to enable a technology for clinical use, which may include manufacturing, intellectual property protection, freedom to operate and market analysis or business case development
- Research and development of techniques or technologies from a different industry sector, which could have a potential impact if applied in a healthcare setting
- Feasibility studies if a technology from a sector other than health is being developed
- Studies to provide data relating to safety and effectiveness of a device including first-in-man and pivotal studies
- Health economic analyses and clinical utility studies looking at a device’s real-life implementation and use
- CE marking and other regulatory requirements including any associated safety trials
- Activities associated with the adoption of new technology
- Training associated with the implementation of new technology
Projects must have already demonstrated ‘proof of principle’. Applicants are expected to have generated experimental data to support the case for further development and illustrate technical feasibility. Early stage research or discovery science is not fundable.
As a translational funding scheme, i4i advances healthcare technologies, devices and interventions for increased patient benefit in areas of existing or emerging clinical need.
NIHR fund collaborative R&D projects in medtech SMEs, universities and the NHS that have demonstrated proof-of-principle and have a clear pathway towards adoption and commercialisation. The aim is to de-risk projects, making them attractive to follow-on funders and investors.
The expected i4i output is an advanced or clinically validated prototype medical device, technology or intervention.
Cresco Innovation works with companies to develop and implement innovation strategies. We help client companies identify opportunities to develop new products and services, and then create a package of support to ensure that the idea is turned into a commercial reality.
Our services include securing grants (as a team we have raised around £40million over three years), business planning, IP advice, access to finance and funders, project management and IP commercialisation support.
We regularly act as the interface with the funding bodies and help clients ensure that their projects are properly managed to ensure the best outcome for all.
Jo has a background in IP commercialisation, having spent more than 25 years in the innovation and enterprise sector. Jo is recognised in the industry for establishing the Loughborough Innovation Centre, where she was the managing director for 15 years.